Jp. Moore et al., STUDIES WITH MONOCLONAL-ANTIBODIES TO THE V3 REGION OF HIV-1 GP120 REVEAL LIMITATIONS TO THE UTILITY OF SOLID-PHASE PEPTIDE BINDING ASSAYS, Journal of acquired immune deficiency syndromes, 7(4), 1994, pp. 332-339
Using human monoclonal antibodies (HuMAbs) r(1)-447 (L-736,523) and 19
b to the V3 region of HIV-1 gp120, we have explored epitope presentati
on on V3-peptides and on the corresponding gp120 proteins. HuMAb r(1)-
447 binds strongly to the MN and SF-2 peptides and gp120 proteins. In
contrast, while this HuMAb binds equally avidly to both the HxB2 and t
he BRU/BH10 peptides, it binds but weakly to the HxB2 V3 loop on gp120
and fails to bind at all to BH10 gp120. Thus, the solid-phase peptide
binding assay can falsely predict reactivity of an MAb with a gp120 p
rotein. Conversely, HuMAb 19b fails to bind to a peptide from the V3 l
oop of HIV-1 AD-6 in solid-phase assays, but binds to the same peptide
in solution and also to AD-6 gp120. Thus, the solid-phase peptide bin
ding assay can fail to predict reactivity of an MAb with a gp120 prote
in. Furthermore, serum antibodies from individual AD-6 do not react we
ll with the AD-6 V3-peptide in a solid-phase assay, but react strongly
with the corresponding MN V3-peptide. On the basis of peptide binding
assays, we had assumed that the AD-6 virus was ''MN-like'' with a pro
totypic North American/European subtype B GPGR motif at the crown of t
he V3 loop. However, direct sequencing demonstrates that the AD-6 V3 l
oop contains a variant GPGK motif. This highlights a limitation of V3-
peptide-based assays for serotyping viruses.